Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07042373 · ClinicalTrials.gov registry record · NA
Effects of Tobacco Abuse Liability-dependent Taxes in the ETM
A NA study, sponsored by Virginia Polytechnic Institute and State University.
- Not yet
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT07042373: Clinical Trial NA study, sponsored by Virginia Polytechnic Institute and State University.
NCT07042373 is a NA study that has not yet begun recruiting, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07042373, a NA study, has not yet begun recruiting, sponsored by Virginia Polytechnic Institute and State University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
In a within-subject design, cigarette smokers, stratified by age, will purchase tobacco products under three tax rate conditions based on abuse liability, that is taxes based on: (1) product category score (i.e. score ranging from 0-1 based on abuse liability effect sizes); (2) product category rank (i.e. position of a product relative to all others; e.g. 1st, 5th); and (3) product tiers (i.e. low-, medium-, high abuse liability), as well as a control. In the ETM, the effects of these interventions will be examined on cigarette demand and other products substitution. The investigators will use a repeated-measures (within subject) analysis of variance (ANOVA) to test if there are differences between conditions (i.e., tax proposals) independently for each product. The models will include study design parameters for order effects to account for counterbalancing the tax conditions in the ETM. Each tax condition will be compared to the control. All distributional assumptions will be checked prior to analyses and the appropriate transformations will be employed, if needed. For each significant result from the omnibus test, the investigators will perform planned contrasts to test the proposed hypotheses previously described. Note that the omnibus test can result in a significant finding while the contrasts of interest may be non-significant. In this case, the investigators will only report the results from the planned contrasts. Additional analyses might be conducted.
Primary Outcome
Participants will complete purchasing trials in an Experimental Tobacco Marketplace (ETM), where nicotine/tobacco prices will increase accordingly with the condition. The quantity of products purchased in the ETM will be converted to milligrams (mg) of nicotine to standardize the unit of measurement across products. The data will reflect the relationship between nicotine purchased (mg; y-axis) and cigarette price (x-axis). Demand will be estimated using the exponential equation: Q = Q0 \* 10\^k(
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Product Category Score
- BEHAVIORAL Product Category Rank
- BEHAVIORAL Product Tiers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2027-04-07 |
| Phase | NA |
What is known before NCT07042373 opens enrollment
NCT07042373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Control is the first listed.
NCT07042373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07042373 about?
NCT07042373 is a clinical study titled "Effects of Tobacco Abuse Liability-dependent Taxes in the ETM". In a within-subject design, cigarette smokers, stratified by age, will purchase tobacco products under three tax rate conditions based on abuse liability, that is taxes based on: (1) product category score (i.e. score ranging from 0-1 based on abuse liability effect sizes); (2) product category rank...
What is the current status of trial NCT07042373?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2026-07-31. Estimated completion is 2027-04-07.
What interventions are being tested in trial NCT07042373?
The interventions under investigation include: Control (BEHAVIORAL), Product Category Score (BEHAVIORAL), Product Category Rank (BEHAVIORAL), Product Tiers (BEHAVIORAL).
Who is sponsoring clinical trial NCT07042373?
This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07042373's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI